Cancilico, a Dresden-based AI diagnostics company focused on blood cancer, has raised €2.5M in seed funding to accelerate the rollout of its software platform for bone marrow analysis. The company aims to make AI-supported diagnostics a routine part of hematology workflows worldwide.
The round was led by High-Tech Gründerfonds, with participation from TGFS – Technologiegründerfonds Sachsen, GEDAD GmbH, and ROI Verwaltungsgesellschaft.
Scaling AI diagnostics for hematological malignancies
Cancilico is developing MyeloAID, an AI-based diagnostic software designed to analyse bone marrow samples with high speed and accuracy. The system is trained on a large, validated dataset that includes samples from patients with hematological malignancies as well as healthy individuals, enabling more precise classification and comparison.
The company is also working with hematopathology centres and pharmaceutical partners to support digital biomarker development and accelerate research into new therapeutic options for blood cancers.
Advertisement
Designed for seamless lab integration
MyeloAID is built as a platform-independent solution that can be used with standard imaging microscopes and scanners. This approach allows laboratories to enhance diagnostic capabilities without replacing existing hardware. The AI-based analysis is already available as a research-use-only solution through Smart In Media’s PathoZoom Scan and LiveView Suite.
Cancilico positions this flexibility as a key advantage at a time when laboratories face increasing diagnostic complexity alongside a global shortage of trained hematologists.
Addressing workforce shortages in hematology
Founded in 2023 as a spin-off from TU Dresden and University Hospital Dresden, Cancilico brings together expertise in data science and clinical hematology. The company’s leadership says its technology is intended to support clinicians by acting as a digital diagnostic counterpart, helping labs handle growing case volumes while maintaining accuracy and consistency.
The new funding will support regulatory preparation for FDA and CE-IVDR approval, product development, and broader market entry.
Expanding access to precision diagnostics
Cancilico plans to use the capital to bring MyeloAID closer to routine clinical use, with the goal of improving diagnostic quality and access to expert-level analysis across healthcare systems. The company sees AI-driven diagnostics as a way to standardise care, reduce turnaround times, and support precision medicine in hematological oncology.
